WO2009046877A3 - Use of a histrelin and leuprolide as therapeutic agents - Google Patents
Use of a histrelin and leuprolide as therapeutic agents Download PDFInfo
- Publication number
- WO2009046877A3 WO2009046877A3 PCT/EP2008/008144 EP2008008144W WO2009046877A3 WO 2009046877 A3 WO2009046877 A3 WO 2009046877A3 EP 2008008144 W EP2008008144 W EP 2008008144W WO 2009046877 A3 WO2009046877 A3 WO 2009046877A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- leu
- histrelin
- leuprolide
- therapeutic agents
- Prior art date
Links
- 108010000817 Leuprolide Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229960002193 histrelin Drugs 0.000 title 1
- 108700020746 histrelin Proteins 0.000 title 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 title 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 title 1
- 229960004338 leuprorelin Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- HHXHVIJIIXKSOE-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[3-(1-benzylimidazol-4-yl)-1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1 Chemical compound CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CC=1C=CC(O)=CC=1)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-UHFFFAOYSA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is directed to the use of the combination of the peptide compounds Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt and Pyr-D-His-Trp- Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPEP07017754.8 | 2007-09-11 | ||
| EP07017751 | 2007-09-11 | ||
| EPEP07017751.4 | 2007-09-11 | ||
| EP07017754 | 2007-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009046877A2 WO2009046877A2 (en) | 2009-04-16 |
| WO2009046877A3 true WO2009046877A3 (en) | 2009-05-28 |
Family
ID=40456203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/008144 WO2009046877A2 (en) | 2007-09-11 | 2008-09-09 | Use of a histrelin and leuprolide as therapeutic agents |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009046877A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| WO2002030351A2 (en) * | 2000-10-13 | 2002-04-18 | Monash University | Improvement of graft acceptance through manipulation of thymic regeneration |
| US20060188521A1 (en) * | 2000-10-13 | 2006-08-24 | Monash University | Treatment of T cell disorders |
| WO2006119388A2 (en) * | 2005-05-03 | 2006-11-09 | Novetide, Ltd. | Methods for the production of peptide having a c-terminal amide |
-
2008
- 2008-09-09 WO PCT/EP2008/008144 patent/WO2009046877A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| WO2002030351A2 (en) * | 2000-10-13 | 2002-04-18 | Monash University | Improvement of graft acceptance through manipulation of thymic regeneration |
| US20060188521A1 (en) * | 2000-10-13 | 2006-08-24 | Monash University | Treatment of T cell disorders |
| WO2006119388A2 (en) * | 2005-05-03 | 2006-11-09 | Novetide, Ltd. | Methods for the production of peptide having a c-terminal amide |
Non-Patent Citations (4)
| Title |
|---|
| BARBIERI ET AL: "Clinical applications of GnRH and its analogues", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 3, no. 1, 1 January 1992 (1992-01-01), pages 30 - 34, XP023117883, ISSN: 1043-2760, [retrieved on 19920101] * |
| CHERTIN ET AL: "AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 163, no. 3, 1 March 2000 (2000-03-01), pages 838 - 844, XP005555991, ISSN: 0022-5347 * |
| FOWLER ET AL: "SAFETY AND EFFICACY OF AN IMPLANTABLE LEUPROLIDE DELIVERY SYSTEM IN PATIENTS WITH ADVANCED PROSTATE CANCER", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 164, no. 3, 1 September 2000 (2000-09-01), pages 730 - 734, XP005553661, ISSN: 0022-5347 * |
| HISTRELIN STUDY GROUP ET AL: "Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 175, no. 4, 1 April 2006 (2006-04-01), pages 1353 - 1358, XP024990022, ISSN: 0022-5347, [retrieved on 20060401] * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009046877A2 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009033821A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043522A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043518A3 (en) | Use of a combination of cart peptides as a therapeutic agent | |
| IL184125A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| TNSN07191A1 (en) | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy | |
| WO2009033819A3 (en) | Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids | |
| IL184124A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| TW200505408A (en) | Agent for preventing and/or treating tissue disruption-accompanied diseases | |
| WO2009033813A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043525A3 (en) | Use of the combination of gluten exorphin c and cd36 as a therapeutic agent | |
| WO2009033814A3 (en) | Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent | |
| WO2009046875A3 (en) | Combination of splenopentin and thymopentin and the use thereof in medicine | |
| WO2009033818A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033820A3 (en) | Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis | |
| WO2009033816A3 (en) | Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent | |
| WO2009033809A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043519A3 (en) | Use of band 3 protein and pacap-27 as a therapeutic agent | |
| WO2009043523A3 (en) | Cortistatin 17 and neuropeptide 1 for use as therapeutic agent | |
| WO2009046877A3 (en) | Use of a histrelin and leuprolide as therapeutic agents | |
| WO2009046876A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046872A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046880A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033812A3 (en) | Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent | |
| WO2009033815A3 (en) | Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent | |
| WO2012004588A3 (en) | Therapeutic agents 976 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08802612 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08802612 Country of ref document: EP Kind code of ref document: A2 |